Quick Take
Aditx Therapeutics (ADTX) has filed to raise $10.5 million in an IPO of its common stock and warrants, according to an S-1 registration statement.
The company is a pre-clinical developer of immune suppression drugs to assist in organ transplantation procedures.
ADTX is still in a very early stage of development, has no formal pipeline and is thinly capitalized, so I'll pass on the IPO.
Company & Technology
Loma Linda, California-based Aditx was founded to license technologies developed at Loma Linda University used in anti-rejection therapies for organ transplant patients.The company